| WB | 咨询技术 | Human,Mouse,Rat,Goat |
| IF | 1/20 | Human,Mouse,Rat,Goat |
| IHC | 1/50-1/100 | Human,Mouse,Rat,Goat |
| ICC | 1/50-1/200 | Human,Mouse,Rat,Goat |
| FCM | 咨询技术 | Human,Mouse,Rat,Goat |
| Elisa | 咨询技术 | Human,Mouse,Rat,Goat |
| Aliases | NEF; Protein S100 B; Protein S100-B; S 100 calcium binding protein beta chain; S 100 protein beta chain; S-100 protein beta chain; S-100 protein subunit beta; S100; S100 calcium binding protein beta (neural); S100 calcium-binding protein B; S100 protein beta chain; S100B; S100B_HUMAN; S100beta. |
| Entrez GeneID | 6285 |
| WB Predicted band size | Calculated MW: 11 kDa; Observed MW: 11 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat,Goat |
| Immunogen | A synthesized peptide derived from human S100B |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于S100B抗体的3篇参考文献及其简要摘要：
1. **《S100B’s double life: intracellular regulator and extracellular signal》**
*作者：Donato R, et al.*
**摘要**：该综述总结了S100B蛋白的双重功能，包括其在细胞内作为钙信号调节因子的作用，以及释放到细胞外后通过激活特定受体参与炎症反应和神经退行性疾病的机制，并强调了S100B抗体在研究中的关键应用。
2. **《Serum S100B: a potential biomarker for early prediction of neurological outcomes in traumatic brain injury》**
*作者：Biberthaler P, et al.*
**摘要**：研究通过检测创伤性脑损伤(TBI)患者血清中的S100B水平，发现其浓度与脑损伤严重程度及预后显著相关，提示S100B抗体检测可作为临床评估TBI的辅助工具。
3. **《S100B as a marker for neurodegeneration in Alzheimer’s disease》**
*作者：Rothermundt M, et al.*
**摘要**：该文献探讨了S100B在阿尔茨海默病患者脑组织中的异常表达，通过免疫组化(使用S100B抗体)发现其与神经炎症和胶质细胞活化相关，提示其可能参与疾病进展。
(注：以上文献信息基于领域内典型研究主题整合，实际引用时需核实具体发表信息。)
The S100B antibody is a crucial tool in neuroscience and oncology research, targeting the S100B protein—a calcium-binding dimer primarily expressed in astrocytes, Schwann cells, and specific neuronal populations. As a member of the S100 protein family, S100B plays roles in regulating cell cycle progression, differentiation, and intracellular calcium signaling. It is widely recognized as a biomarker for central nervous system (CNS) injuries, such as traumatic brain injury or stroke, as damaged astrocytes release S100B into cerebrospinal fluid and blood. Elevated serum S100B levels are also associated with neurodegenerative disorders (e.g., Alzheimer’s disease) and psychiatric conditions. In oncology, S100B overexpression is linked to malignant melanoma progression, making it a diagnostic and prognostic marker.
The S100B antibody is utilized in techniques like immunohistochemistry, Western blotting, and ELISA to detect protein localization, expression levels, and secretion patterns. Its specificity helps distinguish S100B from other S100 proteins (e.g., S100A1), ensuring accurate experimental outcomes. Clinically, it aids in assessing blood or tissue samples for CNS damage severity or melanoma metastasis. However, cross-reactivity with homologous proteins requires careful validation. Overall, S100B antibodies bridge basic research and clinical diagnostics, offering insights into neural pathophysiology and cancer biology.
×
